Cerezyme

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

imiglucerase

Available from:

Sanofi B.V.

ATC code:

A16AB02

INN (International Name):

imiglucerase

Therapeutic group:

Oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti,

Therapeutic area:

Mard Gaucher

Therapeutic indications:

Cerezyme (imiglucerase) huwa indikat għall-użu bħala longterm enżima terapija ta ' sostituzzjoni fil-pazjenti bl-djanjosi konfermat ta ' non-neuronopathic (tip 1) jew neuronopathic kronika (tip 3) mard Gaucher li jesebixxu klinikament sinifikanti nonneurological manifestazzjonijiet tal-marda. Il-manifestazzjonijiet mhux newroloġiċi tal-marda Gaucher jinkludu wieħed jew aktar mill-kondizzjonijiet li ġejjin:anemija wara l-esklużjoni ta 'kawżi oħra, bħal iron deficiencyThrombocytopeniaBone-marda wara l-esklużjoni ta' kawżi oħra bħal Vitamina D deficiencyhepatomegaly jew splenomegalija.

Product summary:

Revision: 31

Authorization status:

Awtorizzat

Authorization date:

1997-11-17

Patient Information leaflet

                                19
B.FULJETT TA’ TAGĦRIF
20
Fuljett ta' tagħrif: Informazzjoni għall-utent
Cerezyme 400 Unità trab għal konċentrat għal soluzzjoni
għall-infużjoni
Imiglucerase
Aqra sew dan l-fuljett ta’ tagħrif kollu qabel tibda tuża din
il-mediċina peress li fih
informazzjoni importanti għalik.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anki jekk ikollhom l-istess sinjali ta’ mard
bħal tiegħek.
-
Jekk ikollok xi effetti sekondarju, kellem lit-tabib jew
lill-ispiżjar tiegħek. Dan jinkludi xi
effett sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’dan il-fuljett
1.
X’inhu Cerezyme u għalxiex jintuża.
2.
X'għandek tkun taf qabel ma tingħata Cerezyme
3.
Kif jingħata Cerezyme.
4.
Effetti sekondarji possibbli.
5.
Kif jinħażen Cerezyme.
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’inhu Cerezyme u għalxiex jintuża
Cerezyme fih is-sustanza attiva imiglucerase u jintuża fil-każ ta’
pazjenti li fid-dijanjosi ġew
ikkonfermati li kellhom it-Tip 1 jew it-Tip 3 tal-marda Gaucher u li
juru sinjali tal-marda bħal:
anemija (numru baxx ta’ ċelluli ħomor tad-demm), tendenza li
jkollhom emorraġiji (minħabba n-
numru baxx ta’ plejtlets - tip ta’ ċellula tad-demm), tkabbir
tal-milsa jew tal-fwied jew mard ta’ l-
għadam.
Persuni li jbatu mill-marda ta’ Gaucher għandhom livelli baxxi
ta’ enżima magħrufa bħala acid -
glucosidase. Din l-enżima tgħin lill-ġisem jikkontrolla l-livelli
tal-glucosylceramide.
Glucosylceramide hi sustanza naturali fil-ġisem, magħmula minn
zokkor u xaħam. Fil-każ tal-marda
Gaucher il-livelli tal-glucosylceramide jistgħu jkunu għoljin aktar
milli suppost.
Cerezyme hi enżima artifiċjali magħrufa bħala imiglucerase – din
tista’ tissostitwixxi l-enżima
naturali acid -glucosidase li tku
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS 1
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Cerezyme 400 Unità Trab għal konċentrat għal soluzzjoni
għall-infużjoni
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull kunjett fih 400 unità* ta’ imiglucerase**.
Wara r-rikonstituzzjoni, is-soluzzjoni fiha 40 unità (madwar 1.0 mg)
ta’ imiglucerase kull ml,
(400 U/10 ml). Kull kunjett irid jiġi dilwit iżjed qabel l-użu (ara
sezzjoni 6.6).
*Unità (U) ta’ enzima hi definita bħala l-ammont ta’ enzima li
tikkatalizza l-idrolisi ta’ mikromol
wieħed tas-substrat sintetiku para-nitrophenyl β-D glucopyranoside
(pNP-Glc) kull minuta
f’temperatura ta’ 37° Ċ.
**Imiglucerase hu forma modifikata ta’ acid -glucosidase uman u
hu magħmul minn teknoloġija
ta’ DNA rikombinanti bl-użu ta’ koltura taċ-ċelluli tal-Ovarju
tal-Ħamster Ċiniż (CHO)
b’modifikazzjoni ta’ mannose biex il-makrofaġi jkunu fil-mira.
Eċċipjenti b’effett magħruf:
Kull kunjett fih 41 mg ta’ sodium.
Għal-lista sħiħa ta' eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Trab għall-konċentrat għal soluzzjoni għall-infużjoni.
Cerezyme hu trab ta’ kulur bejn bajdani u off-white.
4.
TAGĦRIF KLINIKU
4.1
Indikazzjonijiet terapewtiċi
Cerezyme (imiglucerase) hu indikat għall-użu tat-terapija fit-tul li
tinvolvi s-sostituzzjoni enzimatika
f’pażjenti li għandhom dijanjosi konfermata tal-marda Gaucher li
mhix newropatika (Tip 1) jew
newropatika kronika (Tip 3) li juru sinjali tal-marda li huma
klinikament sinifikanti u li mhux
newroloġiċi.
Is-sinjali li mhux newroloġiċi tal-marda Gaucher jinkludu wieħed
jew aktar
mill-kondizzjonijiet li jidhru hawn taħt:

anemija wara l-esklużjoni ta’ kawżi oħra, bħal defiċjenza
tal-ħadid

tromboċitopenija

mard ta’ l-għadam wara l-esklużjoni ta’ kawżi oħra bħal
defiċjenza tal-Vitamina D

epatomegalija jew splenomegalija
4.2
Pożoloġija u metodu ta’ kif għandu jingħata
L-immaniġġjar tal-mard għandu jkun immaniġġjat minn speċjalisti
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 03-04-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 03-04-2023
Public Assessment Report Public Assessment Report Bulgarian 06-10-2010
Patient Information leaflet Patient Information leaflet Spanish 03-04-2023
Public Assessment Report Public Assessment Report Spanish 06-10-2010
Patient Information leaflet Patient Information leaflet Czech 03-04-2023
Public Assessment Report Public Assessment Report Czech 06-10-2010
Patient Information leaflet Patient Information leaflet Danish 03-04-2023
Public Assessment Report Public Assessment Report Danish 06-10-2010
Patient Information leaflet Patient Information leaflet German 03-04-2023
Public Assessment Report Public Assessment Report German 06-10-2010
Patient Information leaflet Patient Information leaflet Estonian 03-04-2023
Public Assessment Report Public Assessment Report Estonian 06-10-2010
Patient Information leaflet Patient Information leaflet Greek 03-04-2023
Public Assessment Report Public Assessment Report Greek 06-10-2010
Patient Information leaflet Patient Information leaflet English 03-04-2023
Public Assessment Report Public Assessment Report English 06-10-2010
Patient Information leaflet Patient Information leaflet French 03-04-2023
Public Assessment Report Public Assessment Report French 06-10-2010
Patient Information leaflet Patient Information leaflet Italian 03-04-2023
Public Assessment Report Public Assessment Report Italian 06-10-2010
Patient Information leaflet Patient Information leaflet Latvian 03-04-2023
Public Assessment Report Public Assessment Report Latvian 06-10-2010
Patient Information leaflet Patient Information leaflet Lithuanian 03-04-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 03-04-2023
Public Assessment Report Public Assessment Report Lithuanian 06-10-2010
Patient Information leaflet Patient Information leaflet Hungarian 03-04-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 03-04-2023
Public Assessment Report Public Assessment Report Hungarian 06-10-2010
Patient Information leaflet Patient Information leaflet Dutch 03-04-2023
Public Assessment Report Public Assessment Report Dutch 06-10-2010
Patient Information leaflet Patient Information leaflet Polish 03-04-2023
Public Assessment Report Public Assessment Report Polish 06-10-2010
Patient Information leaflet Patient Information leaflet Portuguese 03-04-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 03-04-2023
Public Assessment Report Public Assessment Report Portuguese 06-10-2010
Patient Information leaflet Patient Information leaflet Romanian 03-04-2023
Public Assessment Report Public Assessment Report Romanian 06-10-2010
Patient Information leaflet Patient Information leaflet Slovak 03-04-2023
Public Assessment Report Public Assessment Report Slovak 06-10-2010
Patient Information leaflet Patient Information leaflet Slovenian 03-04-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 03-04-2023
Public Assessment Report Public Assessment Report Slovenian 06-10-2010
Patient Information leaflet Patient Information leaflet Finnish 03-04-2023
Public Assessment Report Public Assessment Report Finnish 06-10-2010
Patient Information leaflet Patient Information leaflet Swedish 03-04-2023
Public Assessment Report Public Assessment Report Swedish 06-10-2010
Patient Information leaflet Patient Information leaflet Norwegian 03-04-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 03-04-2023
Patient Information leaflet Patient Information leaflet Icelandic 03-04-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 03-04-2023
Patient Information leaflet Patient Information leaflet Croatian 03-04-2023

Search alerts related to this product

View documents history